Role of inflammatory markers in the diagnosis and management of infective endocarditis

Infectious Diseases in Clinical Practice

Volumn 18, Issue 2, 2010, Pages 87-90

  Watkins, Richard R ^a,b   Lemonovich, Tracy L ^c  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROCALCITONIN; RHEUMATOID FACTOR; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL ENDOCARDITIS; BACTERIUM CULTURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DRUG MONITORING; ERYTHROCYTE SEDIMENTATION RATE; HEART MUSCLE INJURY; HUMAN; INFLAMMATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PROGNOSIS; REVIEW; STAPHYLOCOCCUS INFECTION;

EID: 77952281710     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/IPC.0b013e3181aba67c     Document Type: Review

References (46)

1. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633-638.
2. Lamas CC, Eykyn SJ. Suggested modifications to the Duke criteria for the clinical diagnosis of native valve and prosthetic valve endocarditis: Analysis of 118 pathologically proven cases. Clin Infect Dis. 1997;25:713-719.
3. Tillet WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52:561-571.
4. Castell JV, Gomez-Lechon MJ, David M, et al. Acute phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179-1186.
5. Hansson LO, Hedlund JU, Ortqvist AB. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scand J Clin Lab Invest. 1997;57:111-118.
6. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121:219-225.
7. Martin C, Saux P, Mege JL, et al. Prognositc values of serum cytokines in septic shock. Intensive Care Med. 1994;20:272-277.
8. Chelsom J, Solberg CO. Vertebral osteomyelitis at a Norwegian university hospital 1987-97: clinical features, laboratory findings and outcome. Scand J Infect Dis. 1998;30:147-151.
9. Ghoneim AT, McGoldrick J, Ionescu MI. Serial C-reactive protein measurements in infective complications following cardiac operation: evaluation and use in monitoring response to therapy. Ann Thorac Surg. 1982;34:166-174.
10. Julander I, Svanbom M. Prediction of staphylococcal etiology among patients with septicemia with or without endocarditis by multivariate statistical methods. Scand J Infect Dis. 1985;17:37-46.
11. Hogevik H, Olaison L, Andersson R, et al. C-reactive protein is more sensitive then erythrocyte sedimentation rate for diagnosis of infective endocarditis. Infection. 1997;25:82-85.
12. Gouriet F, Bothelo-Nevers E, Coulibaly B, et al. Evaluation of sedimentation rate, rheumatoid factor, C-reactive protein, and tumor necrosis factor for the diagnosis of infective endocarditis. Clin Vaccine Immunol. 2006;13:301.
13. McCartney AC, Orange GV, Pringle SD, et al. Serum C reactive protein in infective endocarditis. J Clin Pathol. 1988;41:44-48.
14. Delahaye F, Alla F, Beguinot I, et al. In-hospital mortality of infective endocarditis: prognostic factors and evolution over an 8-year period. Scand J Infect Dis. 2007;39:849-857.
15. Verhagen DWM, Hermanides J, Korevaar JC, et al. Extention of antimicrobial treatment in patients with left-sided native valve endocarditis based on elevated c reactive protein. Eur J Clin Microbiol Infect Dis. 2007;26:587-590.
16. Verhagen DWM, Hermanides J, Korevaar JC, et al. Prognostic value of serial C-reactive protein measurements in left-sided native valve endocarditis. Arch Intern Med. 2008;168:302-307.
17. Baddour LM, Wilson WR, Bayer AS. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2005;111: e394-e434.
18. Heiro M, Helenius H, Hurme S, et al. Short-term and one-year outcome of infective endocarditis in adult patients treated in a Finnish teaching hospital during 1980-2004. BMC Infect Dis. 2007;7:78.
19. Heiro M, Helenius H, Sundell J. Utility of serum C-reactive protein assessing the outcome of infective endocarditis. Eur Heart J. 2005;26:1873-1881.
20. Pelletier LL, Petersdorf RG. Infective endocarditis: a review of 125 cases from the University of Washington hospitals, 1963-72. Medicine. 1977;56:287.
21. Olaison L, Hogevik H, Alestig K. Fever, C-reactive protein, and other acute-phase reactants during treatment of infective endocarditis. Arch Intern Med. 1997;157:885-892.
22. Kocazeybek B, Kucukoglu S, Oner YA. Procalcitonin and c-reactive protein in infective endocarditis: correlation with etiology and prognosis. Chemotherapy. 2003;49:76-84.
23. Mueller C, Huber P, Laifer G, et al. Procalcitonin and early diagnosis of infective endocarditis. Circulation. 2004;109:1707-1710.
24. Watkin RW, Harper LV, Vernallis AB, et al. Pro-inflammatory cytokines IL6, TNF-α, IL1β, procalcitonin, lipopolysaccharide binding protein and C-reactive protein in infective endocarditis. J Infect. 2007;55:220-225.
25. Cuculi F, Toggweiler S, Auer M, et al. Serum procalcitonin has the potential to identify Staphylococcus aureus endocarditis. Eur J Clin Microbiol Infect Dis. 2008;27:1145-1149.
26. Rawczynska-Englert I, Hryniewiecki T, Dzierzanowska D. Evaluation of serum cytokine concentrations in patients with infective endocarditis. J Heart Valve Dis. 2000;9:705-709.
27. Soderquist B, Soderquist KG, Jones I, et al. Interleukin-6, C-reactive protein, lactoferrin and white blood cell count in patients with S. aureus septicemia. Scand J Infect Dis. 1995;27:375-380.
28. Alter P, Hoeschen J, Ritter M, et al. Usefullness of cytokines interleukin-6 and interleukin-2R concentrations in diagnosing active infective endocarditis involving native valves. Am J Cardiol. 2002;89:1400-1404.
29. Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000;140:917-927.
30. Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106:2941-2945.
31. Perna ER, Macin SM, Parras JI, et al. Cardiac troponin T levels are associated with poor short and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J. 2002;143:814-820.
32. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116:427-433.
33. Wright RS, Williams BA, Cramner H, et al. Elevations of cardiac troponin I are associated with increased short-term mortality in noncardiac critically ill emergency department patients. Am J Cardiol. 2002;90:634-636.
34. Watkin RW, Lang S, Smith JM, et al. Role of troponin I in active infective endocarditis. Am J Cardiol. 2004;94:1198-1199.
35. Purcell JB, Patel M, Khera A, et al. Relation of troponin elevation to outcome in patients with infective endocarditis. Am J Cardiol. 2008;101:1479-1481.
36. Tsenovoy P, Aronow WS, Joseph J. Patients with infective endocarditis and increased cardiac troponin I levels have a higher incidence of in-hospital mortality and valve replacement than those with normal cardiac troponin I levels. Cardiology. 2009;112:202-204.
37. Kern WV, Engel A, Scheieffer S, et al. Circulating tumour necrosis factor alpha (TNF), soluble TNF receptors, and interleukin 6 in human bacterial endocarditis. Infect Immun. 1993;61:5413-5416.
38. Capo C, Zugun F, Stein A, et al. Up-regulation of tumour necrosis factor alpha and interleukin-1 beta in Q fever endocarditis. Infect Immun. 1996;64:1638-1642.
39. Ekdahl C, Broqvist M, Frazen S, et al. IL-8 and tumor necrosis factor alpha in heart valves from patients with infective endocarditis. Scand J Infect Dis. 2002;34:759-762.
40. Blairon L, Wittebole X, Laterre P. Lipopolysacccharide-binding protein serum levels in patients with severe sepsis due to Gram-positive and fungal infections. J Infect Dis. 2003;187:287-291.
41. Vollmer T, Piper C, Kleesiek K, et al. Lipopolysaccharide-binding protein: a new biomarker for infectious endocarditis? Clin Chem. 2009;55:295-304.
42. Williams RC. Rheumatoid factors in subacute bacterial endocarditis and other infectious diseases. Scand J Rheumatol Suppl. 1988;75:300-308.
43. Williams RC, Kunkel HG. Rheumatoid factor, complement, and conglutinin aberrations in patients with subacute bacterial endocarditis. J Clin Invest. 1962;41:666-675.
44. Messner RP, Laxdal T, Quie PG, et al. Rheumatoid factors in subacute bacterial endocarditis-bacterium, duration of disease or genetic predisposition? Ann Intern Med. 1968;68:746-756.
45. Asherson RA, Tikly M, Staub H, et al. Infective endocarditis, rheumatoid factor, and anticardiolipin antibodies. Ann Rheum Dis. 1990;49:107-108.
46. Sheagren JN, Tuazon CU, Griffrin C, et al. Rheumatoid factor in acute bacterial endocarditis. Arthritis Rheum. 1976;19(5):887-890.